Skip to content
DeepSeq.AI logo — Transforming Protein Design with Explainable AI & Data Gener...

DeepSeq.AI

Transforming Protein Design with Explainable AI & Data Generation at Scale

Founded 2019 United States United States 3 employees Pre-Seed AI, Biotechnology +1

General Information

Company Name DeepSeq.AI
Founded Year 2019
Location United States United States
Employees 3
Industries AI, Biotechnology, Pharmaceutical
Funding Stage Pre-Seed
Social

BounceWatch is an independent company data service, not affiliated with DeepSeq.AI. To contact DeepSeq.AI, visit deepseq.ai.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does DeepSeq.AI compare?

A PDF of DeepSeq.AI and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting DeepSeq.AI soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About DeepSeq.AI

DeepSeq.AI is a groundbreaking startup that is making waves in the field of AI-driven drug discovery. Their unique approach involves the integration of advanced high-throughput wet lab assays with explainable generative AI to craft biologics optimized for diverse essential functions. The company's innovative platform generates extensive-scale protein function data and models protein "grammar," allowing for the development of therapeutics tailored for conditional binding, manufacturability, efficacy, and more. Emphasizing their credibility, DeepSeq.AI has garnered validation from esteemed paying customers, including top global biopharma companies, and has secured a granted patent to protect their pioneering technology. The company's success is further underscored by investments from prominent biotech accelerators like Merck DSS and UC Berkeley SkyDeck, as well as the prestigious NSF SBIR grant. With their foundation in 2019 and headquarters in the United States, DeepSeq.AI is poised to reshape the future of biologics development. Most notably, their significant Pre-Seed Round investment in 01 November 2023 was led by Merck Digital Sciences Studio, highlighting the confidence of industry leaders in the company's potential.

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Pre Seed Round Undisclosed 1
Merck Digital Sciences Studio
01 Nov 2023

FAQ About DeepSeq.AI

Transforming Protein Design with Explainable AI & Data Generation at Scale
DeepSeq.AI was founded in 2019.
DeepSeq.AI is headquartered in United States.
DeepSeq.AI operates in AI, Biotechnology and Pharmaceutical.
DeepSeq.AI has approximately 3 employees.
DeepSeq.AI has completed 1 funding round. The latest funding stage is Pre-Seed.

We're actively collecting intelligence on DeepSeq.AI.

Source: BounceWatch company record for DeepSeq.AI, https://bouncewatch.com/company/deepseqai, updated 24 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout